Belite Bio has an exciting near-term FDA catalyst, while Trevi Therapeutics and COMPASS Pathways could offer substantial long-term upside if their pipelines succeed. However, these opportunities carry greater clinical and regulatory risk.
PTC already has commercial products and growing revenue, giving investors clearer fundamentals to evaluate. I would watch whether sales growth translates into stronger margins and cash flow.
Belite may have greater short-term upside on a positive FDA decision, but for the most compelling overall investment case, I prefer PTC’s combination of commercial traction and future growth potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- dimpy·10-21 16:03PTC still looks like the cleaner setup to me. Revenue growth is nice, but margin expansion and operating cash flow are the real proof from hereLikeReport
- ChristKitto·10-21 16:03PTC is the cleaner setup, but Belite’s Q4 FDA window probably decides the near term. How much of that catalyst is already priced in?LikeReport